295 Exploring Gemcitabine and Zoledronic Acid Effects on Tumour Cell Markers: Implications for Immune Response Enhancement

Aim This study aims to investigate the influence of Gemcitabine (GEM) and Zoledronic Acid (ZA) on critical tumour cell markers—ULBP-1, ULBP-2, ULBP-3, MICA/B, and HLA-1—in order to enhance susceptibility to gamma-delta T cells. The research focuses on understanding how these drugs affect marker expression using Raji, Daudi, and Thp-1 cell lines. Method GEM and ZA were administered at varying concentrations to the cell lines, employing flow cytometry for detailed marker expression analysis. The experiment aimed to observe alterations in the expression levels of ULBP-1, ULBP-2, ULBP-3, MICA/B, and HLA-1 markers following drug exposure. Results ULBP-1 consistently exhibited increased expression across all cell lines, suggesting potential vulnerability of tumour cells to gamma-delta T cell attacks. However, ULBP-2 responses were inconsistent, and ULBP-3 displayed variable patterns based on the specific cell line and treatment regimen. MICA/B expression showed an increase with higher ZA concentrations, though this observation was limited. HLA-1 markers remained relatively stable across cell lines, indicating a consistent population of live cells. Conclusions The findings suggest that GEM and ZA may alter specific tumour cell markers, potentially enhancing vulnerability to immune responses. However, drawing definitive conclusions requires extensive experimentation and statistical analysis due to limitations such as low repetitions. Future research should involve increased repetitions and rigorous statistical tests to determine the significance of these observed marker expression changes. Ultimately, this study sets the groundwork for exploring GEM and ZA as adjuncts to conventional cancer treatments, potentially unlocking their therapeutic potential in enhancing immune responses against tumours.